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osting by EAbstract Aloe vera L. high molecular weight fractions (AHM) containing less than 10 ppm of bar-
baloin andpolysaccharide (MW:1000 kDa)with glycoprotein, verectin (MW:29 kDa),were prepared
by patented hyper-dry system in combination of freeze–dry techniquewithmicrowave and far infrared
radiation. AHMproduced signiﬁcant decrease in blood glucose level sustained for 6 weeks of the start
of the study. Signiﬁcant decrease in triglycerides was only observed 4 weeks after treatment and con-
tinued thereafter. No deterious effects on kidney and liver functions were apparent. Treatment of dia-
betic patientswithAHMmay relief vascular complications probably via activation of immunosystem.
ª 2009 King Saud University. All rights reserved.1. Introduction
Type 2 Diabetes Mellitus (T2DM) is one of the primary threats
to human health due to its increasing prevalence, chronic
course and disabling complications. Synthetic hypoglycemic
drugs cannot fully control glucose level as well as cause side ef-
fects prompting the patients stop taking the medication. Aloe
vera is a widely distributed Liliaceae plant in tropical regions.com (A. Kabbash).
ity. All rights reserved. Peer-
d University.
lsevierand cosmetic and medicinal products are made from the muci-
laginous tissue in the centre of theA. vera calledA. vera gel. The
peripheral bundle of sheath cells produce intensely bitter, yel-
low latex, commonly termed aloe juice, or sap or aloes. Unlike
aloes, A. vera gel contains no anthraquinones, which are
responsible for the strong laxative effects of aloe. The pharma-
cological actions of A. vera was studied in vitro or in vivo (in
most cases the total leaf extract was used), include anti-inﬂam-
matory, anti-arthritic, antibacterial and hypoglycemic effects
(Newall et al., 1996). A. vera is a medicinal plant that is claimed
to have hypoglycemic effect with fewer side effects and less
expensive without toxicity (Bergﬁeld, 2007). The hypoglycemic
efﬁcacy of aloe gel was conﬁrmed in streptozotocin-induced
diabetic rats (Bunyapraphatsara et al., 1995). However, acute
and subchronic toxicity studies of aloe gel (Charles, 1981)
showed no toxic effect when lyophilized aloe gel was adminis-
tered orally to albino rats at doses 1, 4, 16, or 64 mg/kg body
weight twice daily, and the study revealed that the LD50 is over
210 A. Yagi et al.5 g/kg body weight. Studies in mice showed no acute toxicity in
therapeutic doses; however, in high doses a decrease of CNS
activity was observed (Shah et al., 1989). No changes in levels
of serum aspartate aminotransferase (AST), serum alanine ami-
notransferase (ALT), blood urea nitrogen (BUN) and creati-
nine were observed (Wattanasrisin, 1988). Another study
showed the same result with fresh and preserved aloe gel
(Jirakulchaiwong et al., 1991). All these ﬁndings led us to con-
duct a clinical study to investigate the efﬁcacy of Aloe vera high
molecular weight fractions (AHM) prepared by the patented
hyper-dry technique in the treatment of T2DM.2. Materials and methods
2.1. Extraction and preparation
Aloe vera gel high molecular weight fractions (AHM) were ob-
tained from water-washed gel part of Aloe vera leaves culti-
vated in Okinawa, Japan. Voucher specimens of Aloe vera
collected in Okinawa, were compared and determined to be
Aloe vera L. plant (syn. Aloe barbadensis Miller) (Herbarium
number 54-3 in Medicinal garden, Fukuyama University by
Emeritus Prof. A. Yagi). AHM were processed by patented hy-
per-dry system in combination of freeze-dry technique with
microwave and far infrared-ray radiation. AHM contain the
following chemical and physical properties: MW:
1,119,500 Da by HPLC analysis; column, TSK gel GMPW,
two columns in series: 10 lm, 7.8 mm · 30 cm. Eluent: 0.2 M
NaNO3. Flow rate: 1.0 ml/ min. Temperature: 40 C, detection
by refractive index detector.
2.2. Sample treatment
AHM (1 g) sample was homogenized in 2 ml of 0.2 M NaNO3
in a homogenizer. Then, centrifugation of homogenate at
2000g for 1 min was done. Upper solution was introduced as
200 ll aliquots to size exclusion chromatography. Aloin con-
tent is <10 ppm by HPLC analysis (Okamura et al., 1996).
Water content: 3 ± 0.5%, Colony formulating unit: <300/g.
Na+: approx. 430 mg/100 g, Ca2+: approx. 2100 mg/100 g.
Aloe vera high molecular weight fractions, AHM contain the
following characteristics: neutral polysaccharides with MW
of about 1000 kDa, containing 90% carbohydrate and 7%
protein content. Glycoprotein, verectin, composed of carbohy-
drate and protein in a ratio of 10.7% and 82.0%, respectively,
with MW of 29 kDa (Yagi et al., 1997), was obtained in a ratio
of 20% by immunochemical assay in AHM.
Chemical shifts of AHM were determined in D2O with a
JOEL JNM ALPHA-400 and 100 MHz for proton and car-
bon, respectively. The infrared spectra were obtained with a
FTIR-8600PC, Shimadzu, Japan.
1H NMR (ppm, 10 mg/ml in D2O at 34.3 C, TMS as an
internal standard): 2.12 (s, CH3COO), 2.58 (br.s, –C(OH)–
CH2COOH, citric acid), 2.74, 2.78 (d, –CH2CH(OH)COOH,
malic acid), 3.4–4.0, (m, polysaccharides, CH(OH)CH(OH)–),
3.97 (m, –CH2CH(OH)COOH, malic acid), 4.18 (m,
–CH(OH)COOH, malic acid), 5.19, 5.20 (br.s. ano-meric
proton of the non-reducing carbon atom).
13C NMR (ppm, 10 mg/ml in D2O at 34.3 C; TMS as an
internal standard): 62.1 (C6), 70.9, 75.4, 77.0, 77.1, 97.1
(C1), 175.9 (CH3COO).IR (KBr) mmax: 3381 (OH), 2922 (COOH, –NH–), 1735
(CH3COO), 1597 (–NHCO–), 1245 (–CHOH), 1033 (–CHOH).
2.3. Patients
The study protocol was approved by the committee for ap-
proval of the use of human in research of Tanta University
(equivalent to the Institutional Review Board). The protocol
of the study was explained to the patients and they agreed to
participate by signing a written consent form. All procedures
used in the protocol were in accordance to the Helsinki
Declaration.
Fifteen patients (nine males and six females) with T2DM
uncontrolled with their oral hypoglycemic medication (metfor-
min 500 mg twice daily and glibenclamide 5 mg twice daily)
were enrolled in the study. They were selected from the outpa-
tient clinic of the Internal Medicine Department, Tanta Uni-
versity, Egypt. They were selected for the study using the
following criteria:2.4. Inclusion criteria
1. Their ages ranged from 42 to 55 years old.
2. High fasting blood glucose level (>200 mg/dL).
3. Freely consented to participate this study.
2.5. Exclusion criteria
1. Liver disease as deﬁned by abnormal level of ALT, AST
and alkaline phosphatase.
2. Kidney disease as deﬁned abnormal levels of serum BUN
and creatinine.
3. Patients with clinical problems causing hyperglycemia
including infection, and thyroid disease.
4. Patients taken medications known to modify glucose
metabolism as corticosteroids.
5. Morbid obesity (BMI > 40 kg/m2).
2.6. Trial term
Twelve weeks during October, 2007 and December, 2007.
2.7. Consent of patients
We obtained the consents of the patients to this treatment by
document or word of mouth by free will through explaining
the contents to them before preceding the enforcement of this
treatment. In addition, we obtained the consent from the pa-
tient’s family if the patient was unable to judge through Hos-
pital Committee. The research followed guidelines of the
Declaration of Helsinki and Tokyo for humans.
2.8. Design
Before administering AHM, each patient’s body mass index
was calculated (BMI = kg/m2), systolic and diastolic blood
pressure were measured.
All the patients received two tablespoonful (0.05 g) of AHM
three times daily for 12 weeks and continued taking their hypo-
glycemic medications. Blood samples were analyzed for fasting
Table 1 Demographic parameters of the diabetic patient.
Parameters Mean SD
Age (years) 48 4
Diagnosis of DM 2 0.8
Body weight (kg) 74.5 4.4
Length (m) 1.6 0.3
BMI (kg/m2) 29.5 2.2
Systolic pressure (mmHg) 125 8.6
Diastolic pressure (mmHg) 84 5.7
* *
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Figure 1 Effect of treatment with Aloe vera gel on the serum
level of fasting blood glucose, triglyceride, and cholesterol (mg/dl)
in type 2 diabetic patients uncontrolled with their oral hypogly-
cemic medications. – Data are expressed as mean ± SD. *
Indicates signiﬁcantly different from corresponding values before
AHM administration for 12 weeks (p< 0.001). Before = before
AHM administration. After = after AHM administration for 12
weeks.
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glycerides (TG), cholesterol, serum aspartate aminotransferase
(AST), serum alanine aminotransferase (ALT) and serum creat-
inine before the study. Blood samples were obtained again
weekly for measurement of FBG, and every 2 weeks for TG
and cholesterol analysis. The (HbA1c) values were evaluated
every 4 weeks, while serum activities AST and ALT and serum
creatinine levels were determined at the end of the study.
2.9. Serum determinations
Fasting blood glucose was determined by glucose oxidase tech-
nique (Trinder, 1969), using kits obtained from Stanbio Labo-
ratory, Inc., San Antonio, TX. The reaction depends on the
enzymatic oxidation of glucose to gluconic acid and H2O2.
The formed hydrogen peroxide reacts under the inﬂuence of
peroxidase with phenol and aminophenazone to form red–vio-
let quinoneimine dye measured colorimetrically, using UV-
160A Shimadzu Spectrophotometer.
Serum AST and ALT activities were assayed according to
the method of Reitman and Frankel (1957), using kits ob-
tained from Quimica Clinica Aplicadea S.A. Amposta/Spain.
The ketoacids produced by the enzyme action reacts with
2,4-dinitrophenylhydrazine producing hydrazone complex
measureed colorimetrically at 505 nm.
Serum creatinine was measured according to Heinegard
and Tiderstrom (1973) method, using kits obtained from Stan-
bio Laboratory, Inc., San Antonio, TX. Creatinine in picric
acid protein free solution reacts with alkali to form reddish-
brown complex measured colorimetrically at 520 nm.
Serum total cholesterol was determined using kits obtained
from Stanbio Laboratory, Inc., San Antonio, TX. After enzy-
matic hydrolysis of the cholesterol ester, the free cholesterol
was oxidized with cholesterol oxidase. The produced H2O2 re-
acts with phenol and aminophenazone to form red quinineimine
dye measured colorimetrically at 500 nm (Allein et al., 1974).
The triglycerides were determined using kits obtained from
Reactivos Spinreact, S.A. The triglycerides were enzymatically
hydrolyzed to glycerol which phosphorylated by ATP and oxi-
dized to H2O2. The intensity of the ﬁnal red color is propor-
tional to the total triglycerides concentration which
measured at 505 nm (Young and Pestaner, 1975).
Glycosylated Hb (% of total Hb) was measured by chro-
matographic pectrophotometric method according to Bisse
and Abraham (1985) method, using kits obtained from Biosys-
tems S.A. Barcelona (Spain).
2.10. Statistical analysis
Student’s paired t-test was used to determine the difference in
biochemical changes between the patients before and after the
administration of AHM. *P< 0.001.
3. Results
1H NMR studies showed that AHM have polysaccharide moi-
eties with acetyl group in contamination of malic and citric
acid by comparison of chemical shifts with those of Interna-
tional Aloe Science Council data base. On 13C NMR study
AHM is proved to contain acetyl group in polysaccharide moi-
ety, suggesting that acetyl group was preserved by patented hy-
per-dry technique.The demographic parameters of the patients are shown in
Table 1. The BMI values calculated for each patient showed
that all the patients were overweight. Blood pressure measures
showed that none of them was hypertensive. No alterations in
the patient’s blood pressure or a signiﬁcant change in their
body weight could be detected during the study. There were
no adverse effects reported by the patients due to the intake
of AHM. It was well tolerated and there were no complaint
about its taste or smell. Treatment the patients with AHM
for 12 weeks with their oral hypoglycemic agents resulted in
a signiﬁcant decrease in fasting blood glucose by 32% com-
pared to before administration (P< 0.001) (Fig. 1).
The decrease in blood glucose level was signiﬁcant and sus-
tained after 6 weeks from the start of the study (Fig. 2).
The triglycerides level was decreased signiﬁcantly 35%
compared to before treatment with AHM (P< 0.001)
(Fig. 1), the decrease was signiﬁcant after 4 weeks and contin-
ues to fall throughout the study (Fig. 3).
Treatment of the patients with AHM with their oral hypo-
glycemic agents did not result in any change in cholesterol lev-
els compared to before the treatment (Fig. 1).
Glycosylated Hb values calculated for each patient showed
a signiﬁcant reduction by 20% compared to before treatment.
(P< 0.001) (Fig. 4).
Treatment of the patients with AHM did not result in any
change in serum activities of AST, ALT or serum creatinine.
(P< 0.001) (Figs. 5 and 6).
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Figure 5 Effect of treatment with Aloe vera gel on the serum
activities of aspartate aminotransferase (AST) and alanine ami-
notransferase (ALT) (IU/l) in type 2 diabetic patients uncontrolled
with their oral hypoglycemic medications. Data are expressed as
mean ± SD. Before = before AHM administration. After =
after AHM administration for 12 weeks.
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Figure 2 The mean changes of fasting blood glucose levels (mg/
dl) in diabetic patients after administration of AHM for 12 weeks
Data are expressed as mean ± SD. *Indicates signiﬁcantly differ-
ent from corresponding values before AHM administration for 12
weeks (p< 0.001).
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Figure 6 Effect of treatment with Aloe vera gel on the serum
creatinine (mg/dl) in type 2 diabetic patients uncontrolled with
their oral hypoglycemic medications. Data are expressed as
mean ± SD. Before = before AHM administration. After =
after AHM administration for 12 weeks.
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Figure 4 Reduction of the glycosylated hemoglobin values (% of
total Hb) in diabetic patients after administration of AHM for 12
weeks. Data are expressed as mean ± SD.
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Figure 3 The mean changes of triglycerides levels (mg/dl) in
diabetic patients after administration of AHM for 12 weeks. Data
are expressed as mean ± SD.
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The present study aimed to evaluate the hypoglycemic effect of
Aloe vera in diabetic patients uncontrolled with their hypogly-
cemic medications. Administration of AHM three times daily
for 12 weeks concurrently with the oral hypoglycemic drugs re-
sulted in signiﬁcant decrease of the fasting blood glucose level.
The decrease in blood glucose level was signiﬁcant and sus-tained after 6 weeks of the start of the study. HbA1c value
was reduced, a gold standard that conﬁrms a long range level
of the blood glucose, conﬁrming the hypoglycemic effect of
AHM. This results are correlated with other reports that con-
ﬁrm the hypoglycemic effect of aloe in experimental animals
(Beppu et al., 2006; Tanaka et al., 2006; Gundidza et al., 2005).
The anti-diabetic effects of dietary administration of Aloe
arborescens Miller components on multiple low-dose strepto-
zotocin-induced diabetes in mice were investigated. The mice
were fed ad libitum with basal diets supplemented with compo-
nents of Aloe vera. There was no signiﬁcant effect on the blood
glucose level with Aloe vera leaf pulp powder. On the contrary,
the whole aloe leaf signiﬁcantly decreased the blood glucose le-
vel (Beppu et al., 2006).
It has been reported that Aloe vera gel and its derived phy-
tosterols have a long-term blood glucose level control effect
and would be useful for the treatment of type 2 diabetes mel-
litus (Tanaka et al., 2006).
The anti-diabetic activity of Aloe excelsa on male albino
rats was also studied. The study showed that the Aloe excelsa
powder produced a dose-dependent reduction in blood glucose
levels (Gundidza et al., 2005).
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anti-diabetic activity of Aloe vera juice by Yongchaiyudha
et al. (1996), who suggests the potential use of Aloe vera as
an anti-diabetic agent. Agarwal (1985) conducted a clinical
trial on 5000 patients with angina pectoris. He found that add-
ing aloe gel to the diet produced marked reduction in total
cholesterol, triglycerides, fasting and post-brandial blood su-
gar levels in diabetic patients.
In the present study, AHM administration produced a sig-
niﬁcant decrease in the level of triglycerides, the decrease was
signiﬁcant after 4 weeks and continued to fall throughout the
study, however, cholesterol level did not change. These result
was in accordance with that obtained by Rajasekaran et al.
(2006) and Lim et al. (2003).
Rajasekaran et al. (2006) studied the oral administration
of Aloe vera gel extract at a dose of 300 mg/kg body weight
per day to STZ-induced diabetic rats for a period of 21
days. They found that it resulted in a signiﬁcant reduction
in fasting blood glucose, hepatic transaminases (AST and
ALT), plasma and tissue (liver) cholesterol, triglycerides, free
fatty acids and phospholipids and a signiﬁcant improvement
in plasma insulin. In addition, the decreased plasma levels of
high-density lipoprotein-cholesterol and increased plasma
levels of low-density lipoprotein- and very low-density lipo-
protein-cholesterol in diabetic rats were restored to near
normal levels following treatment with the extract. Further-
more, they analyzed the fatty acid composition of the liver
and kidney and found that the altered fatty acid composi-
tion in the liver and kidney of diabetic rats was restored fol-
lowing treatment with the extract. They recommended use of
Aloe vera as an anti-diabetic agent.
Lim et al. (2003) studied the efﬁcacy of dietary Aloe vera
supplementation on hepatic cholesterol and oxidative status
in aged rats. They found that the aloe-supplemented groups
showed approximately 30% lower in the hepatic cholesterol
levels. They concluded that life-long intake of aloe had supe-
rior anti-oxidative action against lipid peroxidation in vivo,
as indicated by reduced levels of hepatic phosphatidylcholine
hydroperoxide, and had hypocholesteremic efﬁcacy.
In the present study, administration of AHM did not result
in any change in serum AST, ALT activities, or serum creati-
nine, indicating its safety to liver and kidney.
Chudan et al. (2007) validated the hepatoprotective po-
tential of Aloe barbadensis Mill against carbon tetrachloride
induced hepatotoxicity. The hepatoprotective activity was
evident by restoration of serum transaminases, alkaline
phosphatase, bilirubin and triglycerides. It was conﬁrmed
by the restoration of lipid peroxidation, glutathione, glu-
cose-6-phosphatase and microsomal aniline hydroxylase
and amidopyrine N-demethylase towards near normal. Fur-
thermore, histopathology of the liver tissue supported the
biochemical ﬁndings.
Bolkent et al. (2004) found that the degenerative changes
observed in the kidney tissue of streptozotocin-induced type
2 diabetic rats were diminished when they were given glibencla-
mide and aloe leaf gel and pulp extracts. Serum urea and cre-
atinine levels were higher in diabetic rats in comparison to
healthy rats. The administration of aloe gel extract and gliben-
clamide decreased serum urea and creatinine levels in compar-
ison to diabetic controls. Only Aloe vera leaf gel extract
showed improvement both in histological and biochemicalparameters suggesting a protective effect of Aloe vera on mild
damage caused by type 2 diabetes on kidney tissue.
Sulfonylurea is initially successful in treatment T2DM,
but it is often associated with failure (Matthews et al.,
1998). This failure also occurs during multi-drug therapy
using a combination of sulfonylurea and oral anti-diabetic
agents with different mechanisms poor compliance, lack of
adequate diet regimen, body weight gain, deterioration of
insulin sensitivity, presence of anti-islet cell and antiglutamic
acid decarboxylase antibodies and decline in pancreatic b-
cell function which is the strong predictor causative factor
(Fukui et al., 1997).
Obesity increases the risk of diabetes due to insulin resis-
tance. This may be due to the production of various factors de-
rived from the adipocyte that act on fat, liver, or muscle to
impair insulin action.
Obesity itself is also associated with hyper-insulinemia,
and insulin may induce insulin resistance through down reg-
ulation of the insulin receptor. Potential candidate sub-
stances produced by fat that may cause insulin resistance
include tumor necrosis factor (TNF) and other cytokines
such as interleukin-6 (IL-6) and adiponectin (Hajer et al.,
2008).
Aloe vera gel (AHM) act as thromboxane A2 inhibitor. It
promotes vasodilatation and maintains hemostasis within the
vascular endothelium as well as within the surrounding tissue
(Heggers et al., 1993). In earlier study we reported that verec-
tin, a glycoprotein, indicated anti-oxidative, anti-thromboxane
A2 synthase inhibition and cyclooxygenase-2 inhibiting activi-
ties in vitro (Yagi et al., 2003), those of which may be deeply
correlated with vasodilatation in DM patients. By use of poly-
clonal antibody to verectin generated in rabbit serum, it was
demonstrated that AHM containing immunoreactive verectin
in a ratio of 20% (Yagi et al., 1997, 2000a,b) inhibited serum
FBG and triglyceride levels.
The present clinical study was carried out using AHM
including polysaccharides (MW about 1000 kD) and verectin
(MW: 29 kD), with contamination of barbaloin <10 ppm
and hypoglycemic efﬁcacy for T2DM patients by oral admin-
istration for 12 weeks was revealed without any side effects.
Therefore, treatment with AHM may relief peripheral blood
vessel complications in diabetic patients through activation
of immunosystem. Furthermore, AHM containing about
MW 1000 kD was biodegraded by intestinal microbials into
oligosaccharides (Yagi et al., 1999, 2001) which inhibit absorp-
tion of glucose moiety through gut membrane (Jain et al.,
2007).
AHM is a high molecular weight natural polysaccharide
contains glucomannan polysaccharide with acetyl group
(acemannan). The effect of mannan on triglyceride level was
estimated by Boban et al. (2006) as well as by Sood et al.
(2008) which is due to inhibition of the hepatic production
of chylomicron.
5. Conclusion
AHM with <10 ppm of barbaloin prepared by patented hy-
per-dry system exhibited a signiﬁcant hypoglycemic effect, it
can lower not only the glucose but also the triglycerides level
which are often high in diabetic patients with no hepato- and
nephrotoxicity.
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